CervoMed Inc. (CRVO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CervoMed Inc. (CRVO) has a cash flow conversion efficiency ratio of -0.755x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.02 Million) by net assets ($10.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can CervoMed Inc. fund operations to measure how many days the company can operate on defensive assets alone.
CervoMed Inc. - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how CervoMed Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
CervoMed Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CervoMed Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aytu BioScience Inc
NASDAQ:AYTU
|
-0.119x |
|
Medhelp Care AB
ST:MEDHLP
|
0.163x |
|
Richmond Vanadium Technology Ltd
AU:RVT
|
-0.017x |
|
Newtree S.A
BR:NEWT
|
0.060x |
|
Keller Group PLC
LSE:KLR
|
0.077x |
|
Orcay Ortakoy Cay Sanayi & Ticaret AS
IS:ORCAY
|
0.063x |
|
Indo Acidatama Tbk
JK:SRSN
|
0.060x |
|
S2 Resources Ltd
AU:S2R
|
-0.100x |
Annual Cash Flow Conversion Efficiency for CervoMed Inc. (1998–2025)
The table below shows the annual cash flow conversion efficiency of CervoMed Inc. from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see CervoMed Inc. (CRVO) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.22 Million | $-23.45 Million | -1.287x | -205.17% |
| 2024-12-31 | $39.20 Million | $-16.53 Million | -0.422x | +58.25% |
| 2023-12-31 | $7.38 Million | $-7.45 Million | -1.010x | -453.20% |
| 2022-12-31 | $-9.00 Million | $-2.57 Million | 0.286x | +168.83% |
| 2021-12-31 | $34.91 Million | $-14.50 Million | -0.415x | +23.94% |
| 2020-12-31 | $24.81 Million | $-13.55 Million | -0.546x | -11.55% |
| 2019-12-31 | $20.13 Million | $-9.86 Million | -0.490x | +29.04% |
| 2018-12-31 | $15.61 Million | $-10.77 Million | -0.690x | -18.79% |
| 2017-12-31 | $21.23 Million | $-12.33 Million | -0.581x | +50.45% |
| 2016-12-31 | $9.18 Million | $-10.77 Million | -1.172x | -100.94% |
| 2015-12-31 | $-41.62K | $-5.19 Million | 124.578x | +52752.75% |
| 2014-12-31 | $38.17 Million | $-9.03 Million | -0.237x | -29.13% |
| 2013-12-31 | $6.47 Million | $-1.18 Million | -0.183x | -178.24% |
| 2012-12-31 | $-18.41 Million | $-4.31 Million | 0.234x | -68.84% |
| 2011-12-31 | $-16.00 Million | $-12.02 Million | 0.751x | +100.77% |
| 2010-12-31 | $20.22K | $-1.98 Million | -97.964x | -4474.39% |
| 2009-12-31 | $493.60K | $-1.06 Million | -2.142x | -85.81% |
| 2008-12-31 | $438.99K | $-505.95K | -1.153x | +61.74% |
| 1999-12-31 | $2.77 Million | $-8.35 Million | -3.012x | -133.32% |
| 1998-12-31 | $5.50 Million | $-7.10 Million | -1.291x | -- |
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and sl… Read more